In our study group, glycaemic disturbances requiring permanent insulin therapy (DM), defined as the need for insulin therapy 3 months after KTx and 12 months after KTx, were noticed at a rate of 19% and 27% in the HIL group and the LIL group, respectively. The gene discussed is INS; the disease is diabetes mellitus.